These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 25555733)

  • 41. GPI 6150 prevents H(2)O(2) cytotoxicity by inhibiting poly(ADP-ribose) polymerase.
    Zhang J; Lautar S; Huang S; Ramsey C; Cheung A; Li JH
    Biochem Biophys Res Commun; 2000 Nov; 278(3):590-8. PubMed ID: 11095954
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Poly(ADP-ribose) polymerase inhibitors counteract diabetes- and hypoxia-induced retinal vascular endothelial growth factor overexpression.
    Obrosova IG; Minchenko AG; Frank RN; Seigel GM; Zsengeller Z; Pacher P; Stevens MJ; Szabó C
    Int J Mol Med; 2004 Jul; 14(1):55-64. PubMed ID: 15202016
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Design, Synthesis, and Evaluation of New Quinazolinone Derivatives that Inhibit Bloom Syndrome Protein (BLM) Helicase, Trigger DNA Damage at the Telomere Region, and Synergize with PARP Inhibitors.
    Wang CX; Zhang ZL; Yin QK; Tu JL; Wang JE; Xu YH; Rao Y; Ou TM; Huang SL; Li D; Wang HG; Li QJ; Tan JH; Chen SB; Huang ZS
    J Med Chem; 2020 Sep; 63(17):9752-9772. PubMed ID: 32697083
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The inhibition of poly(ADP-ribose) polymerase enhances growth rates of ataxia telangiectasia cells.
    Marecki JC; McCord JM
    Arch Biochem Biophys; 2002 Jun; 402(2):227-34. PubMed ID: 12051667
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?
    Papeo G; Forte B; Orsini P; Perrera C; Posteri H; Scolaro A; Montagnoli A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1377-400. PubMed ID: 19743897
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Synthesis and activity evaluation of PARP-1 inhibitors with azaindole skeleton].
    Zhou J; Zhu ZX; Chen XG; Xu BL
    Yao Xue Xue Bao; 2013 Dec; 48(12):1792-9. PubMed ID: 24689236
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel class of substituted spiro [quinazoline-2,1'-cyclohexane] derivatives as effective PPAR-1 inhibitors: molecular modeling, synthesis, cytotoxic and enzyme assay evaluation.
    Amin KM; Anwar MM; Syam YM; Khedr MA; Kamel MM; Kassem EM
    Acta Pol Pharm; 2013; 70(4):687-708. PubMed ID: 23923393
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The discovery and synthesis of novel adenosine substituted 2,3-dihydro-1H-isoindol-1-ones: potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1).
    Jagtap PG; Southan GJ; Baloglu E; Ram S; Mabley JG; Marton A; Salzman A; Szabó C
    Bioorg Med Chem Lett; 2004 Jan; 14(1):81-5. PubMed ID: 14684303
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of potent and selective PARP-1 and PARP-2 inhibitors: SBDD analysis via a combination of X-ray structural study and homology modeling.
    Ishida J; Yamamoto H; Kido Y; Kamijo K; Murano K; Miyake H; Ohkubo M; Kinoshita T; Warizaya M; Iwashita A; Mihara K; Matsuoka N; Hattori K
    Bioorg Med Chem; 2006 Mar; 14(5):1378-90. PubMed ID: 16288880
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthesis and
    Guleria M; Kumar A; Singh AK; Kumar P
    Comb Chem High Throughput Screen; 2024; 27(9):1329-1343. PubMed ID: 37691193
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Construction of pharmacophore model of PARP-1 inhibitor].
    Zhang WT; Yan H; Jiang FC
    Yao Xue Xue Bao; 2007 Mar; 42(3):279-85. PubMed ID: 17520827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Design, synthesis and biological evaluation of pyridazino[3,4,5-de]quinazolin-3(2H)-one as a new class of PARP-1 inhibitors.
    Wang J; Tan H; Sun Q; Ge Z; Wang X; Wang Y; Li R
    Bioorg Med Chem Lett; 2015 Jun; 25(11):2340-4. PubMed ID: 25899312
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1(2H)-ones and preliminary evaluation as inhibitors of poly(ADP-ribose)polymerase (PARP).
    Watson CY; Whish WJ; Threadgill MD
    Bioorg Med Chem; 1998 Jun; 6(6):721-34. PubMed ID: 9681138
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel quinazolin-4-one derivatives as potentiating agents of doxorubicin cytotoxicity.
    Pospisilova M; Andrs M; Seifrtova M; Havelek R; Jun D; Tomsik P; Prchal L; Dolezal R; Tichy A; Kucera T; Korabecny J; Rezacova M
    Bioorg Chem; 2019 Feb; 82():204-210. PubMed ID: 30326402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Exploring the effect of PARP-1 flexibility in docking studies.
    Antolin AA; Carotti A; Nuti R; Hakkaya A; Camaioni E; Mestres J; Pellicciari R; Macchiarulo A
    J Mol Graph Model; 2013 Sep; 45():192-201. PubMed ID: 24056306
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis, [¹⁸F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography.
    Zhou D; Chu W; Xu J; Jones LA; Peng X; Li S; Chen DL; Mach RH
    Bioorg Med Chem; 2014 Mar; 22(5):1700-7. PubMed ID: 24503274
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synthesis and structure-activity relationships of novel poly(ADP-ribose) polymerase-1 inhibitors.
    Tao M; Park CH; Bihovsky R; Wells GJ; Husten J; Ator MA; Hudkins RL
    Bioorg Med Chem Lett; 2006 Feb; 16(4):938-42. PubMed ID: 16290935
    [TBL] [Abstract][Full Text] [Related]  

  • 58. 2-Arylquinazolin-4(3H)-ones: A novel class of thymidine phosphorylase inhibitors.
    Javaid S; Saad SM; Perveen S; Khan KM; Choudhary MI
    Bioorg Chem; 2015 Dec; 63():142-51. PubMed ID: 26547232
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of low micromolar dual inhibitors for aldose reductase (ALR2) and poly (ADP-ribose) polymerase (PARP-1) using structure based design approach.
    Chadha N; Silakari O
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2324-2330. PubMed ID: 28438542
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Discovery and structure-activity relationship of novel 2,3-dihydrobenzofuran-7-carboxamide and 2,3-dihydrobenzofuran-3(2H)-one-7-carboxamide derivatives as poly(ADP-ribose)polymerase-1 inhibitors.
    Patel MR; Bhatt A; Steffen JD; Chergui A; Murai J; Pommier Y; Pascal JM; Trombetta LD; Fronczek FR; Talele TT
    J Med Chem; 2014 Jul; 57(13):5579-601. PubMed ID: 24922587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.